scholarly journals Efficacy of low-dose EarthTec® QZ treatment for the control of New Zealand mud snails Potamopyrgus antipodarum in a hatchery environment

2021 ◽  
Vol 12 (1) ◽  
pp. 85-95
Author(s):  
Devon Oliver ◽  
Alex Loubere ◽  
Jeff Sorensen
Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1184
Author(s):  
Robyn N. Hall ◽  
Tegan King ◽  
Tiffany O’Connor ◽  
Andrew J. Read ◽  
Jane Arrow ◽  
...  

Rabbit haemorrhagic disease virus 2 (RHDV2 or GI.2, referring to any virus with lagovirus GI.2 structural genes) is a recently emerged calicivirus that causes generalised hepatic necrosis and disseminated intravascular coagulation leading to death in susceptible lagomorphs (rabbits and hares). Previous studies investigating the virulence of RHDV2 have reported conflicting results, with case fatality rates ranging from 0% to 100% even within a single study. Lagoviruses are of particular importance in Australia and New Zealand where they are used as biocontrol agents to manage wild rabbit populations, which threaten over 300 native species and result in economic impacts in excess of $200 million AUD annually to Australian agricultural industries. It is critically important that any pest control method is both highly effective (i.e., virulent, in the context of viral biocontrols) and has minimal animal welfare impacts. To determine whether RHDV2 might be a suitable candidate biocontrol agent, we investigated the virulence and disease progression of a naturally occurring Australian recombinant RHDV2 in both 5-week-old and 11-week-old New Zealand White laboratory rabbits after either high or low dose oral infection. Objective measures of disease progression were recorded through continuous body temperature monitoring collars, continuous activity monitors, and twice daily observations. We observed a 100% case fatality rate in both infected kittens and adult rabbits after either high dose or low dose infection. Clinical signs of disease, such as pyrexia, weight loss, and reduced activity, were evident in the late stages of infection. Clinical disease, i.e., welfare impacts, were limited to the period after the onset of pyrexia, lasting on average 12 h and increasing in severity as disease progressed. These findings confirm the high virulence of this RHDV2 variant in naïve rabbits. While age and infectious dose significantly affected disease progression, the case fatality rate was consistently 100% under all conditions tested.


Check List ◽  
2020 ◽  
Vol 16 (3) ◽  
pp. 621-626 ◽  
Author(s):  
Gonzalo A. Collado ◽  
Carmen G. Fuentealba

The New Zealand mudsnail Potamopyrgus antipodarum (Gray, 1843) has been considered as one of the most invasive mollusks worldwide and recently was listed among the 50 most damaging species in Europe. In the present paper, we report for the first time the presence of P. antipodarum in the Maule river basin, Chile. The identity of the species was based on anatomical microdissections, scanning electron microscopy comparisons, and DNA barcode analysis. This finding constitutes the southernmost record of the species until now in this country and South America.


Author(s):  
Heather Thon ◽  
Amy Krist

Understanding invasive species impacts is critical to determining how an ecosystem may function after an introduction. Invasive species can alter the structure and function of ecosystems, reduce biological diversity, and alter communities through predation, facilitation and competition. In the past 30 years, the invasive New Zealand mud snail (Potamopyrgus antipodarum) has established in areas of conservation concern in the American West including Yellowstone National Park. To develop a greater understanding of the impact of P. antipodarum on the native co-occurring snail, Fossaria (Bakerilymnaea) bulimoides group, we conducted two experiments to assess the interactions occurring between these snails. We found that F. bulimoides growth was reduced by all interactors, but especially by P. antipodarum. In addition, growth of F. bulimoides was much more affected by high biomass of snails than P. antipodarum. P. antipodarum grew more in the presence of interactors and their growth was facilitated by the presence of the native snail F. bulimoides.


2008 ◽  
Vol 3 (3) ◽  
pp. 349-353 ◽  
Author(s):  
Timothy Davidson ◽  
Valance Brenneis ◽  
Catherine de Rivera ◽  
Robyn Draheim ◽  
Graham Gillespie

Author(s):  
Jeremy A. Geist ◽  
Jasmine L. Mancuso ◽  
Morgan M. Morin ◽  
Kennedy P. Bommarito ◽  
Emily N. Bovee ◽  
...  

2020 ◽  
pp. archdischild-2019-318733
Author(s):  
Lisa Jean Kremer ◽  
Roland Broadbent ◽  
Natalie Medlicott ◽  
Mary Jane Sime ◽  
Frances McCaffrey ◽  
...  

AimsTo determine ifVery low dose mydriatic eye microdrop regimen sufficiently dilates the pupil (above 4.1 mm) compared with the currently used low dose mydriatic eye microdrop regimen.Cardiovascular, gastrointestinal and respiratory adverse effects occur following eye drop instillation.MethodsSeventeen premature infants were recruited into this prospective, randomised controlled pilot trial in January 2017 to November 2018. Data were collected from the single-centre Neonatal Intensive Care Unit, Dunedin Hospital, New Zealand. The inclusion criteria were birth weight less than 1500 g or gestational age less than 31 weeks, or any premature infant requiring red reflex testing. Infants were randomised to receive either phenylephrine 1% or 0.5% and cyclopentolate 0.2% or 0.1%, 1 microdrop in both eyes. Efficacy outcome measures were pupil size at retinopathy of prematurity eye examination (ROPEE) and ophthalmologist rating of ease of screen.ResultsAll participants had sufficient pupillary dilation for a successful ROPEE. Ophthalmologists rated the ROPEE as easy for 90% of all examinations. Pupil dilation measurements at the time of examination, mean±SD, 4.8±0.2 (95% CI 4.5 to 5.2) mm for treatment A and 5±0.2 (95%CI 4.6 to 5.4) mm for treatment B (p=0.61). There were no statistically significant differences between the groups for safety data.ConclusionsVery low dose microdrop administration of phenylephrine and cyclopentolate appears to be effective at sufficiently dilating the neonatal pupil for ROPEEs. Low dose and very low dose microdrop mydriatic regimens may also reduce the risk of unwanted adverse effects associated with these medicines.Trial registration numberAustralian New Zealand Clinical Trials Registry (reference ACTRN12616001266459p).


Sign in / Sign up

Export Citation Format

Share Document